2 weeks ago
Symbiotec Pharmalab to Raise ₹1,757 Crore Through IPO
Symbiotec Pharmalab is a company that makes medicines and ingredients used in medicines.
It wants to collect ₹1,757 crore by selling shares to the public.
Some of the money will come from new shares issued by the company, while existing investors will sell some of their shares.
The new money raised by the company will be used partly to repay debt.
Its shares will be offered at ₹938 to ₹988 each.
People must buy at least 15 shares at a time.
Symbiotec makes products using chemistry, biotechnology and complex injectable medicines.
Its shares are planned to begin trading on the BSE and NSE on September 1.
Symbiotec Pharmalab plans to raise up to ₹1,757 crore through a combination of a fresh issue and an offer for sale.
The IPO price band is ₹938-988 per share, valuing the company at about ₹6,350 crore at the upper end.
The fresh issue of up to ₹150 crore will fund debt repayment and general corporate purposes.
Promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund–III will sell shares worth ₹1,607 crore.
The Indore-based company reported ₹110 crore profit and ₹869 crore revenue for the financial year ended March 2026.
- Who
- Symbiotec Pharmalab, along with promoter Satwani Holdings LLP and selling investors Rosewood Investments and India Business Excellence Fund–III.
- What
- A planned initial public offering to raise up to ₹1,757 crore.
- Where
- Symbiotec is based in Indore, Madhya Pradesh, and proposes listing its shares on the BSE and NSE.
- When
- The IPO is scheduled to open on Monday, with listing proposed for September 1; the announcement was published August 19, 2026.
- Why
- The company will use proceeds from the fresh issue for debt repayment and general corporate purposes, while existing shareholders will sell part of their holdings.
Key facts
- IPO size
- Up to ₹1,757 crore
- Fresh issue
- Up to ₹150 crore
- Offer for sale
- Up to ₹1,607 crore
- Price band
- ₹938-988 per equity share
- Minimum bid
- 15 equity shares, and multiples of 15 thereafter
- FY2026 profit
- ₹110 crore, up from ₹97 crore in the previous fiscal year
- FY2026 revenue
- ₹869 crore, up from ₹752 crore in the previous fiscal year
- Proposed listing
- BSE and NSE on September 1
Sources
Related news
Symbiotec Pharmalab IPO Draws Strong, Conflicting Subscription Figures
Symbiotec Pharmalab IPO Opens With ₹1,757 Crore Offer
Symbiotec Pharmalabs IPO Opens With 42% Grey-Market Premium
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
Investors Buy 10.4% Stake in Symbiotec Ahead of IPO
PVR Inox Buyback: September 3 Last Day to Buy
Indian Stocks Extend Three-Day Losing Streak as Oil Rises
Augmont Enterprises Rises Despite Gold-Buying Appeal and Market Risks
BSE Shares Fall as New Closing Auction Session Draws Scrutiny
Spice Lounge Food Works Stock Hits Upper Circuit Amid Crash
